Business Wire

VIKING-MALT

1.2.2024 09:01:30 CET | Business Wire | Press release

Share
Viking Malt partners up with Improvin’ to reduce supply chain emissions in barley

Viking Malt has set Science Based Targets, committing to a 42% reduction in greenhouse gas emissions from its own activities (Scope 1 & 2) by 2030. However, the majority of Viking Malt’s total emissions, 87%, are Scope 3 emissions from their suppliers, mainly occurring on-farm.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240201888552/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Viking Malt, a globally acknowledged producer of malt, is introducing a new sustainability performance platform, developed by the Swedish technology company Improvin’. Photo: Viking Malt.

Many of Viking Malt’s customers are large enough to have reduction targets covering even their Scope 3 emissions. To support their clients in achieving this goal, Viking Malt is committed to working with its stakeholders across the supply chain, identifying areas for emissions reductions and adjusting processes and practices.

With barley sourced from farmers across Finland, Sweden, Denmark, Poland and Lithuania, Viking Malt has been seeking ways to effectively measure and reduce these emissions.

Annika Wilhelmson, VP of Sustainability, Innovation & Marketing at Viking Malt Group: “Our farmers are central to our sustainability journey. With this new platform, we're empowering over 1200 farmers across Europe to actively engage in climate-smart and sustainable farming. This enables us to track and validate the impact of their sustainable practices effectively and fosters a collaborative approach to reducing emissions.”

The new platform provides Viking Malt with a detailed overview of the farms’ sustainability performance, setting a foundation for sustainable farming initiatives in which growers can adjust their practices based on feedback that builds on real-time data.

With the platform’s scalable data collection, farmer reporting becomes easy. “We want our farmers to be able to focus on sustainable and profitable agriculture, not extensive reporting,” Annika emphasizes.

The new platform equips Viking Malt with a verified ingredient footprint, biodiversity data and supply chain insights that they can share with their network of breweries, distilleries and food manufacturers. Viking Malt expects this transparency to drive positive change across the industry.

Annika concludes: “Our commitment to sustainable food and beverage production is shared by the industry. Success requires a collaborative approach throughout, and even beyond, our own value chain. We're excited to lead and inspire our partners and customers on this journey.”

Niklas Wallsargård, CEO of Improvin’ adds: “We're both proud and excited to work with Viking Malt, a family company showing deep commitment to drive sustainable impact through their products. Together, we can drive a meaningful change in this industry.”

About Viking Malt

Viking Malt is a globally acknowledged producer of malt for breweries, distilleries, and food manufacturers. With six malt houses in Sweden, Denmark, Finland, Lithuania, and Poland, Viking Malt offers a diverse range of malt varieties, catering to the unique needs of their customers. The company advocates for increased sustainability through malt by promoting regenerative farming practices, continuously improving energy and water efficiency in the malting process, reducing emissions, and leading innovation in new types of malts.

About Improvin’

Improvin’ is a Swedish technology company providing a sustainability performance platform for the agri-food industry. Food brands, processors and mills use the platform to quantify, verify and report emissions from their primary production and collaborate with their suppliers to reduce emissions and enhance biodiversity. Improvin's digital infrastructure enables agri-food businesses to incorporate sustainability into their existing sourcing processes while meeting regulatory standards for reporting with primary data.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240201888552/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye